---
document_datetime: 2024-07-04 11:43:17
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abilify-maintena-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: abilify-maintena-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.5156618
conversion_datetime: 2025-12-22 16:43:28.255494
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Abilify Maintena

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0051              | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product | 21/06/2024                          |                                             | SmPC, Labelling and PL           |           |
| IB/0050              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                           | 31/05/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0049             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 31/05/2024 25/01/2024   | 25/03/2024   | PL SmPC, Labelling and PL   |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------|-----------------------------|-----------------------------------|
| X/0045 PSUSA/234/2 | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Periodic Safety Update EU Single assessment - | 07/03/2024              | n/a          |                             | PRAC Recommendation - maintenance |
| 02307 IA/0047/G    | aripiprazole This was an application for a group of variations.                                                                                                        | 02/08/2023              | n/a          |                             |                                   |
| N/0046             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 20/07/2023              | 25/03/2024   | Labelling                   |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0044   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/10/2022   | n/a        |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IB/0043/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products | 21/01/2022   | n/a        |                        |
| IB/0042   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 13/10/2021   | 29/09/2022 | SmPC, Labelling and PL |
| II/0040   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/07/2021   | n/a        |                        |
| IB/0041   | B.II.d.2.d - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/06/2021   | n/a        |                        |

<div style=\"page-break-after: always\"></div>

|                   | product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                 |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/234/2 02007 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/02/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                               |
| IB/0039/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ | 18/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                 |
| II/0035           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/09/2020 | 27/10/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                 |
| II/0037           | To update the product information with \"DRESS' as new identified ADR in section 4.8 of the SmPC and subsequently in section 4 of the package leaflet according to the current CCDS version. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                         | 10/09/2020 | 27/10/2020 | SmPC and PL                      | The product information has been updated to reflect \"DRESS' as new identified ADR. Please refer to Scientific Discussion 'Product Name-H-C-002755-II-Var.No 0037' For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                   | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                          |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036/G         | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 23/07/2020 | n/a        |             |                                                                                                                                          |
| PSUSA/234/2 01907 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/02/2020 | 28/04/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/234/201907. |
| IB/0032/G         | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                              | 21/11/2019 | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                   | manufacturing sites B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |            |             |                                                                                                                                          |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0033/G       | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                               | 15/10/2019 | n/a        |             |                                                                                                                                          |
| PSUSA/234/2 01807 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/02/2019 | 29/04/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/234/201807. |
| IA/0031           | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                                           | 10/04/2019 | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0030           | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                | 14/12/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                          | 14/12/2018   | 29/04/2019 | PL                     |                                                                                                                                                                                                                                                                                |
| IA/0029/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.e.7.z. - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other variation | 12/12/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                |
| T/0026            | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                       | 14/09/2018   | 16/10/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                |
| R/0025            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                   | 28/06/2018   | 27/08/2018 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Abilify Maintena in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/234/2 01707 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                | 08/02/2018   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                              |
| II/0023           | Update of sections 4.4 and 4.8 of the SmPC with further information about the risk of impulse control                                                                                                                                                                                                                                                                     | 26/10/2017   | 27/08/2018 | SmPC, Labelling and    | Patients can experience increased urges, particularly for gambling, and the inability to control these urges while                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                   | disorders, and section 4.8 of the SmPC to include the new ADRs 'impulse control disorders', 'binge eating', 'compulsive shopping' and 'poriomania'. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes and align the annexes with the latest QRD template. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   |            |            | PL          | taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole.   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                              | 03/05/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/234/2 01607 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/02/2017 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/234/2       | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/02/2016 | 28/04/2016 | SmPC and PL | Please refer to Abilify - PSUSA/00000234/201507 EPAR:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| 01507     | aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       | Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0019    | Update of the package leaflet with revised contact details of the local representatives for Austria, Belgium, Luxembourg, Croatia and Iceland. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/04/2016 | 27/08/2018 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0018   | Update of the SmPC sections 4.4 and 5.1 to reflect data from Clinical Trials 31-12-291 and 31-12-297 in patients with acute episodes of schizophrenia and to warn against use of Abilify Maintena in case of severe attacks requiring immediate symptom control. The Package leaflet is updated accordingly. In addition, the MAH took the opportunity to include information on the effect of Abilify Maintena on prolactin levels in section 5.1 of the SmPC in support of an existing cross-reference from section 4.8, to align the PI with the latest QRD template version 9.1 and to introduce minor editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/01/2016 | 28/04/2016 | SmPC, Annex II and PL | Section 5.1 of the Abilify Maintena Summary of Product Characteristics (SmPC) was updated to include clinically relevant information for the prescriber in relation to the treatment of acute relapses of schizophrenia based on results from the double-blind, phase 3 trial 31-12-291 and from its 6-month open-label extension (Trial 31-12-297). There was a relevant weight and akathisia increase that was more frequent than when Abilify Maintena was studied for maintenance treatment, which is reflected in the new wording added to SmPC section 5.1. Additionally, a warning statement advising against the use of Abilify Maintena in case of severe attacks requiring immediate symptom control was added to section 4.4 of the SmPC. |
| IB/0016/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 19/06/2015 | 28/04/2016 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                   | Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/234/2 01407 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/02/2015 | 24/04/2015 | SmPC and PL                      | Please refer to Abilify and Abilify Maintena PSUSA/0234/201407 EPAR: Scientific conslusions and grounds recommending the variation to the terms of the marketing authorisation |
| II/0011/G         | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                   | 26/03/2015 | 28/04/2016 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                |
| IAIN/0015/G       | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. | 25/03/2015 | 28/04/2016 | SmPC, Labelling and PL           |                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------|
| IB/0014   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                         | 05/02/2015 | n/a        |                        |      |
| II/0012/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 22/01/2015 | 24/04/2015 | SmPC, Labelling and PL | data |
| IA/0013   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                     | 19/12/2014 | n/a        |                        |      |
| IB/0010   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                 | 17/12/2014 | 24/04/2015 | SmPC and PL            |      |
| IAIN/0007 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                | 17/07/2014 | n/a        |                        |      |

<div style=\"page-break-after: always\"></div>

| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/06/2014   | 24/04/2015   | Labelling              |                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------|
| IB/0004   | The MAH proposes to present all presentations for each strength in one single SmPC and to combine the Package leaflet. In addition, the use of the abbreviation \"IM\" for \"intramuscular\" is proposed in the Labelling for the vial. In line with the SmPC, information related to method of administration has been added in the outer carton. An editorial change was also made in section 4.2 of the SmPC with deletion of a bullet point. Furthermore, the use of EN translation of INNs was introduced in the Annexes (powder vial only) for Austria, Belgium Bulgaria, Germany, Greece, Spain, Croatia, Ireland, Iceland, Malta, Netherlands and Norway. The use of Latin translation of INNs was introduced in the Annexes (powder vial only) for Czech Republic, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Poland, Romania, Slovenia, Slovak Republic and Sweden. C.I.z - Changes (Safety/Efficacy) of Human and | 28/03/2014   | 24/04/2015   | SmPC, Labelling and PL | Veterinary Medicinal |
| IA/0003/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/02/2014   | n/a          |                        |                      |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |     |                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------|
| IA/0001/G | This was an application for a group of variations.                                                                                                                           | 10/01/2014 | n/a | B.II.b.2.a - Change to importer, batch arrangements and quality control testing |